SinglePoint, Inc. (OTC: $SING) Updates Shareholders on Initiatives to Strengthen Corporate Value

SinglePoint, Inc. (OTC: $SING) Updates Shareholders on Initiatives to Strengthen Corporate Value 

SEATTLE (May 03, 2017) (Investorideas.com Newswire) SinglePoint, Inc. (OTC: SING), a holding company specialized in the acquisition of small to mid-sized companies with an emphasis on new technologies, today issues an update on current and future initiatives to maximize corporate value and increase shareholder communication.

SinglePoint recently enhanced its corporate website, www.SinglePoint.com, to provide investors a clear view of the company’s endeavors and market value. SinglePoint.com is designed to increase shareholder value by driving more engagement for[SF1]  potential acquisitions [SF2] and sales for the acquired companies. Investors can sign up for updates by visiting http://ir.singlepoint.com/email-alerts, and can access the latest research report on SinglePoint at LAdavisandassociates.com

Through online marketing and key partnerships, SinglePoint plans to execute its growth strategy to drive revenues through acquisitions and utilize inside sales efforts to maintain a low overhead.

Greg Lambrecht, SinglePoint CEO, states, “This is an exciting time for SinglePoint. We continue to increase value for our shareholders by focusing on acquisitions while strengthening inside sales and fund raising. We expect 2017 to be a great year for SinglePoint and look forward to providing additional updates on future acquisition targets, joint ventures, and new products.”

SinglePoint also launched its cannabis brand subsidiary, www.SingleSeed.com, for the online sale of cannabis products to cannabis dispensaries. To increase its visibility, SingleSeed.com also provides a list of upcoming tradeshows it will attend and offers an interactive Cannabis Laws Map to serve as a hub of information on cannabis laws in each state. Leveraging key distribution agreements and a highly-integrated marketing plan, SingleSeed is expected to drive significant sales this year.

“The long-term vision is to build SingleSeed.com into a market-place for dispensaries to buy the products they need to do business,” says Lambrecht. “SingleSeed will also provide consulting services to cannabis businesses who need help gaining traction and success in their strategies.”

SinglePoint is currently in negotiations for more acquisition in the cannabis space, a market expected to reach $24.5 billion by the year 2025. The company recently funded Convectium, the developer of a unique oil filling machine and a leader in the cannabis market space. Convectium sells a line of products on its website, www.Convectium.com, and sells its industry leading machines at 710shark.com. The machine will soon be available on SingleSeed.com as well.

“We are pleased to provide these updates to our shareholders, and look forward to announcing progress on additional initiatives such as acquisitions, development of mobile applications, and additional payment processing options,” says Lambrecht. “We have built a foundation of growth for 2017 and look forward to watching it take root.”

Previously Greg Lambrecht, as the founder and largest shareholder, took PCI, a distribution company to the NASDAQ on a $10,000,000 IPO. His distribution experience is a major competitive advantage to place the company’s products in stores throughout the nation. [SF3] 

Read this release in full at http://www.investorideas.com/CO/SING/news/2017/05031Updates.asp

About SinglePoint, Inc.

SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.

Connect on social media at: www.facebook.com/SinglePointMobile, www.twitter.com/_SinglePoint_, www.linkedin.com/company/SinglePoint and www.youtube.com/user/SinglePointMobile

For more information visit www.SinglePoint.com or www.SingleSeed.com

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact:

SinglePoint, Inc.
Greg Lambrecht
602.481.1544

Disclosure: SinglePoint, Inc. (OTC: $SING) is featured on the 420 Cannabis Investor Ideas of 2017 at www.420cannabisinvestorideas.com

Marijuana / Hemp Stocks

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

https://www.youtube.com/watch?v=e2zFezO580Y&t=54s

Disclaimer: This directory is not a recommendation to buy or sell securities or products or services Investorideas.com charges a fee for placement. The directory is not an endorsement or recommendation but meant to be an investor resource/ due diligence tool.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Companies Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to $1000 to be featured on the directory and is also a featured cannabis company for news and PR, social media for one month

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Cytomegalovirus ( #CMV) News; VBI Vaccines (Nasdaq: $VBIV) (TSX: $VBV) Reports on its Congenital CMV Phase I Clinical Study

Cytomegalovirus ( #CMV) News; VBI Vaccines (Nasdaq: $VBIV) (TSX: $VBV) Reports on its Congenital CMV Phase I Clinical Study

Congenital  #CMV infection is a leading cause of birth defects, affecting more live births than #Downsyndrome or #fetalalcoholsyndrome

CAMBRIDGE, MA - May 3, 2017 (Investorideas.com Newswire)   Breaking Vaccine News: VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) ("VBI") provides an update on its cytomegalovirus ("CMV") Phase I clinical study, which is assessing the safety and tolerability of VBI's vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is a leading cause of birth defects, affecting more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority.

Upon review of all safety data up to one month after second immunizations in VBI's prophylactic CMV Phase I clinical study, the Data and Safety Monitoring Board ("DSMB") unanimously recommended the continuation of the study without modification. No safety signals have been detected, suggesting VBI's CMV vaccine candidate is safe and well-tolerated.

Additionally, all participants in the study have now successfully received the third and final immunization in the series. Further vaccine immunogenicity and safety follow-up are ongoing.

An interim safety and immunogenicity report, based on blood samples collected from participants one month post-second vaccination, is expected mid-year 2017.

Read this release in full at http://www.investorideas.com/news/2017/biotech/05031VBIVaccines.asp

                       

About the Phase I Clinical Study Design

The Phase I study is designed to assess the safety and tolerability of VBI’s CMV vaccine candidate in approximately 125 healthy CMV-negative adults. The study will also determine the vaccine immunogenicity by measuring levels of vaccine-induced CMV neutralizing antibodies, which may prevent CMV infection.

Additional information, including a detailed description of the study design, eligibility criteria, and investigator sites, is available at ClinicalTrials.gov using identifier NCT02826798.

About the Data and Safety Monitoring Board

The DSMB was formed with key opinion leaders, a statistician, and experts in safety in clinical studies of this nature. The board is an arms-length committee that monitors the clinical study to assess safety data at various time points during the clinical study, and to recommend to VBI whether to continue, modify, or stop the study.

About CMV

CMV can cause serious disease in newborns when a mother is infected during pregnancy. Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, which can include deafness, blindness, and mental retardation. CMV affects more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority and a strong candidate for recommended universal vaccination and reimbursement.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac™ is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology enables the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

·        Website Home: https://www.vbivaccines.com/  

·        News and Insights: https://www.vbivaccines.com/wire/

·        Investors: https://www.vbivaccines.com/investors/  

VBI Contact

Perri Maduri, Communications Executive

Phone: (617) 830-3031

Email: info@vbivaccines.com

VBI Investor Contact

Nell Beattie

Director, Corporate Development and Investor Relations

Email: IR@vbivaccines.com

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “may”, “plan”, “will”, “suggesting”, “expected”, and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements, including statements regarding: plans for Phase III clinical studies, the provision of additional information about clinical studies, the safety and tolerability of the congenital CMV vaccine candidate, the provision of an interim safety and immunogenicity report, and the potential effects of Sci-B-Vac™.

Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.

Although management believes that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate. Actual results and developments may differ materially from those expressed or implied by the forward-looking statements contained herein and even if such actual results and developments are realized or substantially realized, there can be no assurance that they will have the expected consequences or effects. Factors which could cause actual results to differ materially from current expectations include: the failure to successfully develop or commercialize the company’s products; adverse changes in general economic conditions or applicable laws, rules and regulations; and other factors detailed from time to time in the company’s reports filed with the U.S Securities and Exchange Commission and the Canadian Securities Commissions.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure – the following is a paid news release for VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) Learn more about our newswire . pricing and how to publish your news- http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

#AI/Sports/Media News: Breaking Data (TSX: $BKD.V; OTC: $BKDCD) Announces Independent Directors

#AI/Sports/Media News: Breaking Data (TSX: $BKD.V; OTC: $BKDCD) Announces Independent Directors

Greg D'Alba former President and Chief Operating Officer of #CNN; Matt Elek currently CEO for #Vice in Europe, the Middle East and Africa

TORONTO, ONTARIO and LONDON, UNITED KINGDOM - May 3, 2017 (Investorideas.com Newswire) #AI/Sports/Media News: Breaking Data Corp. (TSX VENTURE:BKD) (OTC PINK:BKDCD) (the "Company" or "BKD") reports that is has now finalized its new independent Director appointees with key industry veteran leadership and experience.

"We are extremely privileged to have this group of experienced and successful directors join our board," said Nick Thain, CEO. "These executives not only bring a vast network of knowledge but also have deep ties in many sports related businesses across the globe, that cross into our key markets. They will, no doubt, be valuable to our strategic and business progress."

Read this release in full at http://www.investorideas.com/news/2017/artificial-intelligence/05031BreakingData.asp

The new team of independent directors includes:

Greg D'Alba: Mr. D'Alba is currently the Co- founder & CEO of VIDL NEWS LLC, a start-up artificial intelligence news venture focused on real-time personalized news intelligence and reporting. Previously he served as President of Global Partnerships at WME - IMG, a global leader in sports, events, media and fashion, operating in more than 30 countries (img.com). In his leadership role, D'Alba oversaw all brand partnerships and managed the company's global sales and marketing strategies. Prior to joining WME - IMG in 2014, Mr. D'Alba was the President and Chief Operating Officer of CNN, overseeing all ad sales, marketing, and business operations for the CNN portfolio of networks worldwide.

Matt Elek: Mr. Elek is currently the CEO for Vice in Europe, the Middle East and Africa. As head of Vice's business in EMEA, Matt oversees a network of 40+ companies spread across 60+ territories with over 1000 full time regional staff, multiple media streams and hundreds of millions in turnover. Vice's regional footprint includes a robust digital business, an extensive television footprint, print, agency services and other media offerings in 12 languages, reaching hundreds of millions of consumers each month.

Ben Nicholas: Mr. Nicholas is head of UK Media and Global Digital Sales for IMG Media. In this role, he combines rights acquisitions, sales and client and broadcast relationships in the UK market along with devising and implementing IMG Media's overall content strategy in the digital space on a global basis. In his role within the UK, Ben oversees all media rights related commercial activities concerning major clients such as the Rugby World Cup, Scottish FA US Open tennis, Tennis Masters Series, European Tour, R&A, Moto GP, Diamond League Athletics, and the NHL. His main business focus is the sale of rights for the above clients in the UK market and their ongoing representation around the globe.

Roger Mitchell: Mr. Mitchell is a chartered accountant and investment banker. He has worked with PWC and James Capel and held senior finance roles with WPP and EMI. He has 20 years of experience in sports and was the founding Chief Executive of the Scottish Premier League and a member of UEFA's Professional Football Committee. He continues to assist clubs and federations as an advisor.

Roger Rai: Mr. Rai is the Managing Director of E.S. Rogers Enterprises. In his capacity as Managing Director, Roger advises Edward Rogers, the representative controlling shareholder of Rogers Communications, on business development, revenue development, talent development and sports. Roger is also the President of R3 Concepts Inc., a company that acts as a basis for investments he makes and consulting services he provides. Prior to which, Roger was the Vice President, Business Development, Keek Inc. (TSX VENTURE:KEK). In his role at Keek, he oversaw and advised on many corporate issues which range from operational to board/corporate governance affairs. He is currently an advisor to Chobani, Inc., a retail food services company, and is the founder and on the board of the ONEXONE foundation, a charitable organization focused on global child welfare.

About Breaking Data Corp.: http://www.breakingdatacorp.com/

Breaking Data Corp. is a technology provider of semantic search, machine learning and natural language processing ("NLP"). The Company's technology platform has many practical applications, in multiple business and consumer verticals that are immersed in massive media and data rich settings. The Company's showcase app, BreakingSports, utilizes semantic machine learning and NLP to track social media in a fully automated, real-time manner for significant sports information and events and distributes summarized information through real-time push notifications to consumers. Find out more at breakingdatacorp.com.

About GiveMeSport: http://www.givemesport.com/

GiveMeSport, Breaking Data's recent acquisition, is a leading next generation sports media company with the largest single publisher Facebook page in the world, with over 25.9 million fans. The next largest single sports publisher Facebook page is ESPN with 15.2 fans. GiveMeSport's content generates over 3.6 billion impressions (Feb-17), reaching over 138 million unique users (Feb-17) per month on Facebook alone.  https://www.facebook.com/GiveMeSport/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-looking Statements - Statements contained in this news release, which are not historical facts, are forward-looking statements that involve risk, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements included in this news release are based on information available to the Company on the date hereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results of the Company to differ materially from the conclusion, forecast or projection stated in such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to factors referenced in the Company's other continuous disclosure filings, which are available at sedar.com. Readers should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statements, except as required by applicable securities laws.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure : Breaking Data Corp is a paid PR, news and social media client on Investorideas.com effective May 2, 2017 ( one month ten thousand per month  ) 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

VBI Vaccines @VBIVaccines (Nasdaq: $VBIV) (TSX: $VBV) Provides Update on its Congenital #CMV Phase I Clinical Study

VBI Vaccines @VBIVaccines (Nasdaq: $VBIV) (TSX: $VBV) Provides Update on its Congenital #CMV Phase I Clinical Study

Positive Safety Review and Final Vaccination of All Participants

CAMBRIDGE, MA (May 2, 2017) – (Investorideas.com Newswire) VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety and tolerability of VBI’s vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is a leading cause of birth defects, affecting more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority.

Upon review of all safety data up to one month after second immunizations in VBI’s prophylactic CMV Phase I clinical study, the Data and Safety Monitoring Board (“DSMB”) unanimously recommended the continuation of the study without modification. No safety signals have been detected, suggesting VBI’s CMV vaccine candidate is safe and well-tolerated.

Additionally, all participants in the study have now successfully received the third and final immunization in the series. Further vaccine immunogenicity and safety follow-up are ongoing.

An interim safety and immunogenicity report, based on blood samples collected from participants one month post-second vaccination, is expected mid-year 2017.

Read this release in full at http://www.investorideas.com/news/2017/biotech/05021VBIV.asp

                       

About the Phase I Clinical Study Design

The Phase I study is designed to assess the safety and tolerability of VBI’s CMV vaccine candidate in approximately 125 healthy CMV-negative adults. The study will also determine the vaccine immunogenicity by measuring levels of vaccine-induced CMV neutralizing antibodies, which may prevent CMV infection.

Additional information, including a detailed description of the study design, eligibility criteria, and investigator sites, is available at ClinicalTrials.gov using identifier NCT02826798.

About the Data and Safety Monitoring Board

The DSMB was formed with key opinion leaders, a statistician, and experts in safety in clinical studies of this nature. The board is an arms-length committee that monitors the clinical study to assess safety data at various time points during the clinical study, and to recommend to VBI whether to continue, modify, or stop the study.

About CMV

CMV can cause serious disease in newborns when a mother is infected during pregnancy. Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, which can include deafness, blindness, and mental retardation. CMV affects more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority and a strong candidate for recommended universal vaccination and reimbursement.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac™ is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology enables the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

·        Website Home: https://www.vbivaccines.com/  

·        News and Insights: https://www.vbivaccines.com/wire/

·        Investors: https://www.vbivaccines.com/investors/  

VBI Contact

Perri Maduri, Communications Executive

Phone: (617) 830-3031

Email: info@vbivaccines.com

VBI Investor Contact

Nell Beattie

Director, Corporate Development and Investor Relations

Email: IR@vbivaccines.com

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “may”, “plan”, “will”, “suggesting”, “expected”, and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements, including statements regarding: plans for Phase III clinical studies, the provision of additional information about clinical studies, the safety and tolerability of the congenital CMV vaccine candidate, the provision of an interim safety and immunogenicity report, and the potential effects of Sci-B-Vac™.

Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.

Although management believes that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate. Actual results and developments may differ materially from those expressed or implied by the forward-looking statements contained herein and even if such actual results and developments are realized or substantially realized, there can be no assurance that they will have the expected consequences or effects. Factors which could cause actual results to differ materially from current expectations include: the failure to successfully develop or commercialize the company’s products; adverse changes in general economic conditions or applicable laws, rules and regulations; and other factors detailed from time to time in the company’s reports filed with the U.S Securities and Exchange Commission and the Canadian Securities Commissions.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure – the following is a paid news release for VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) Learn more about our newswire . pricing and how to publish your news- http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

NXT-ID, Inc. (Nasdaq: $NXTD) Releases Preliminary Results for the Quarter Ended March 31, 2017

NXT-ID, Inc. (Nasdaq: $NXTD) Releases Preliminary Results for the Quarter Ended March 31, 2017

MELBOURNE, Florida, May 2, 2017 – (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) ("NXT-ID" or the "Company"), a security technology company, announces selected preliminary results for quarter ended March 31, 2017.

Read this release in full at http://www.investorideas.com/CO/NXT/news/2017/05021Results.asp

First Quarter Highlights:

·        Revenue for Q1 2017 was approximately $6.6 million compared to $42,302 for the same period in previous year and $4.5 million for Q4 2016.

·        Quarter on quarter revenue growth was approximately 46%.

·        Gross profit for Q1 2017 was approximately $3.5 million compared to a gross loss of $(32,853) in Q1 2016 and a gross profit of $2.0 million for Q4 2016.

·        Quarter on quarter gross profit growth was approximately 75%.

·        Operating expenses were approximately $2.4 million in Q1 2017 compared to $2.3 million in Q1 2016. Operating expenses were $2.6 million in Q4 2016.

·        Operating income for Q1 2017 was approximately $1 million compared to an operating loss of $(2.3) million in Q1 2016. The operating loss in Q4 2016 was $(0.6) million.

"Our first quarter results for 2017 show continued substantial growth following the significant progress we reported in Q4 2016,” said Gino Pereira, Chief Executive Officer of NXT-ID. “LogicMark had a record sales month during the first quarter and we have started to deliver the flye card in significant quantities to World Ventures in anticipation of their product launch. We remain confident that we will continue the improvement in our operating results during the remainder of 2017 and look forward to the forthcoming merger with Fit-Pay, Inc. to further broaden our capabilities and customers.”

Preliminary Results 

The results provided in this press release are preliminary and subject to completion of Nxt-ID's financial statements for the quarter ended March 31, 2017 in conjunction with the Company's Form 10-Q filing for the same period, and therefore they are subject to change.

Nxt-ID intends to report final results for the quarter ended March 31, 2017 on or about May 15, 2017, after market close.

About NXT- ID Inc. - Mobile Security for a Mobile World 

Nxt-ID, Inc. (NASDAQ: NXTD) is a security technology Company providing security for finance, assets and healthcare. The Company’s innovative MobileBio® solution mitigates risks associated with mobile computing, m-commerce and smart OS-enabled devices. With extensive experience in biometric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, the Company partners with industry leading companies to provide solutions for modern payment and the Internet of Things (“IoT”) applications. The Company’s wholly owned subsidiary, LogicMark, LLC, manufactures and distributes nonmonitored and monitored personal emergency response systems (“PERS”) sold through the United States Department of Veterans Affairs (“VA”), healthcare durable medical equipment dealers and distributors and monitored security dealers and distributors.

http://nxt-id.com/  http://www.logicmark.com

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT-ID Inc. Contact:

Corporate info: info@nxt-id.com

Media:

D. Van Zant
1-800-665-0411
press@nxt-id.com

SOURCE NXT-ID, Inc

Visit this company: nxt-id.com; 3d-id.net; 

wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure:

Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Nxt-ID, Inc. (NXTD) is a long term paid news publication and PR client of Investorideas.com. Renewed October 1, 2016 – see details at http://www.investorideas.com/About/News/Clientspecifics.asp